AGENUS INC | 3,084 Euro | -0,186 -5,69 % | |
| WKN: A1JLKZ ISIN: US00847G7051 Ticker-Symbol: AJ81 | Frankfurt | 23.05.13 | 15:36 Uhr |
Branche BiotechnologieAktienmarkt Sonstige |
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 22.05. | Agenus begins Phase 2 trials of brain tumor vaccine | 2 | bizjournals | |
| 22.05. | AGENUS INC - 8-K, Current Report | 1 | SEC Filings | |
| 10.05. | AGENUS INC - 10-Q, Quaterly Report | - | SEC Filings | |
| 03.05. | Possible Bullish Inside Day Candle Pattern Detected for Antigenics | 1 | SmarTrend | |
| 01.05. | Agenus trial of brain cancer vaccine shows better survival rate | 3 | bizjournals | |
| 01.05. | AGENUS INC - 8-K, Current Report | - | SEC Filings | |
| 29.04. | Agenus: Near-Term Drivers With A Market Opportunity Over $17 Billion | 4 | Seeking Alpha | |
| 24.04. | Agenus' CEO Discusses Q1 2013 Results - Earnings Call Transcript | 1 | Seeking Alpha | |
| 24.04. | AGENUS INC - 8-K, Results of Operations and Financial Condition Financial Statements and Exhibits | 1 | SEC Filings | |
| 16.04. | AGENUS INC - 8-K, Entry into a Material Definitive Agreement Creation of a Direct Financial ... | 2 | SEC Filings | |
| 19.03. | Agenus' Roth Annual Conference Presentation - Transcript | 2 | Seeking Alpha | |
| 17.01. | InterMune Inc., Novartis, Celgene Corporation, Targacept Inc. and Agenus Inc. highlighted in Zacks Analyst Blog | 161 | PR Newswire | |
| CHICAGO, Jan. 17, 2013 /PRNewswire/ --Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events... Mehr lesen zu: InterMune Inc., Novartis, Celgene Corporation, Targacept Inc. and Agenus Inc. highlighted in Zacks Analyst Blog | ||||
| 09.11. | Agenus Says Phase 3 Study Of GSK's Mosquirix Meets Primary Endpoint | 64 | AFX News | |
| LONDON (dpa-AFX) - Agenus Inc. (AGEN) announced the second complete set of
results from the Phase 3 trial of GlaxoSmithKline's (GSK, GSK.L) RTS,S malaria
vaccine candidate (also known as... Mehr lesen zu: Agenus Says Phase 3 Study Of GSK's Mosquirix Meets Primary Endpoint | ||||
| 18.07. | Zacks.com featured expert Kevin Matras highlights: Affymax, Inc., Agenus Inc., Demand Media, Inc., M.D.C. Holdings Inc. and Scorpio Tankers Inc. | 44 | PR Newswire | |
| CHICAGO, July 18, 2012 /PRNewswire/ -- Stocks in this week's article include: Affymax, Inc. (NASDAQ: AFFY), Agenus Inc. (NASDAQ: AGEN), Demand Media, Inc. (NYSE: DMD), M.D.C. Holdings Inc. (NYSE:... Mehr lesen zu: Zacks.com featured expert Kevin Matras highlights: Affymax, Inc., Agenus Inc., Demand Media, Inc., M.D.C. Holdings Inc. and Scorpio Tankers Inc. | ||||
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| EVOTEC | 2,766 | -2,50 % | Evotec-Aktie: Jetzt einsteigen! |
| XOMA | 3,08 | -5,64 % | Ladenburg hebt das Kursziel für XOMA von $5 auf $6. |
| CELLDEX THERAPEUTICS | 9,418 | -6,04 % | Celldex Therapeutics Bullish Moving Average Crossover Alert |
| PAION | 0,699 | -1,55 % | Paion: 10 Prozent Aufschlag |
| VICAL | 2,67 | -3,71 % | Biotech Stock Mailbag: Vical, Sangamo, Spectrum Pharma |
